Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

A Population-Based Study on Survival of 652 Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in Italy

Barbara Mora, Giacomo Pellegrini, Matteo Franchi, Olivia Leoni, Daniela D'Ippoliti, Valeria Di Fabrizio, Fabrizio Gemmi, Claudia Szasz, Margherita Maffioli, Carmelo Gurnari, Enrico Attardi, Giovanni Corrao, Paola Guglielmelli, Maria Teresa Voso, Alessandro Maria Vannucchi, Francesco Passamonti

Blood (2023) 142 (Supplement 1): 4572.

https://doi.org/10.1182/blood-2023-182107

Published: 2023

Journal Articles

Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera

Julian Waksal, Ronald Hoffman, Abdulraheem Yacoub, Francesco Passamonti, Aaron T. Gerds, Vikas Gupta, Grace Van Hyfte, Jayanshu Jain, Margherita Maffioli, Natalia Rosas, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2023-182116

Published: 2023

Journal Articles

A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region

Barbara Mora, Giacomo Pellegrini, Matteo Franchi, Margherita Maffioli, Marco Brociner, Paola Guglielmelli, Maria Teresa Voso, Tiziana Ottone, Marta Ubezio, Giulia Maggioni, Michele Merli, Alessandro M. Vannucchi, Matteo G. Della Porta, Giovanni Corrao, Francesco Passamonti

Blood (2022) 140 (Supplement 1): 9737–9739.

https://doi.org/10.1182/blood-2022-164575

Published: 2022

Journal Articles

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Blood (2022) 140 (Supplement 1): 1504–1506.

https://doi.org/10.1182/blood-2022-162207

Published: 2022

Journal Articles

Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Francesco Passamonti, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Brian Higgins, Ling-Yuh Huw, PhD, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD, John Mascarenhas, MD

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-136135

Published: 2020

Journal Articles

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

John Mascarenhas, MD, Brian Higgins, Doreen Anders, Kate Burbury, MD, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Bruno Kovic, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD

Blood (2020) 136 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2020-135868

Published: 2020

Journal Articles

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Blood (2019) 134 (Supplement_1): 2946.

https://doi.org/10.1182/blood-2019-124854

Published: 2019

Journal Articles

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

Simona Soverini, PhD, Luana Bavaro, Margherita Martelli, Caterina De Benedittis, PhD, Alessandra Iurlo, Nicola Orofino, MD, Livio Pagano, Marianna Criscuolo, Massimiliano Bonifacio, Luigi Scaffidi, MD, Simona Sica, MD, Federica Sorà, MD, Elena Maino, Michela Rondoni, MD, Maria Antonella Laginestra, PhD, Francesca Lunghi, Anna Ermacora, Mariella D'adda, MD, Gabriele Gugliotta, MD PhD, Fausto Castagnetti, Gianantonio Rosti, Cristina Papayannidis, Giovanni Marconi, Antonio Curti, Maria Cristina Miggiano, Sara Galimberti, Antonio Percesepe, MD PhD, Fabio Stagno, Rosaria Sancetta, MD, Mario Annunziata, Franca Falzetti, MD, Isabella Capodanno, Patrizia Pregno, Margherita Maffioli, MD, Tamara Intermesoli, MD, Eros Di Bona, MD, Giovanni Caocci, MD, Imma Attolico, MD, Gianni Binotto, Monica Bocchia, MD PhD, Emanuele Angelucci, MD, Nicola Sgherza, MD, Luigiana Luciano, Flavio Mignone, Stefano A. Pileri, MD PhD, Giovanni Martinelli, Michele Cavo, MD

Blood (2018) 132 (Supplement 1): 789.

https://doi.org/10.1182/blood-2018-99-117166

Published: 2018

Journal Articles

Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study

Maria Gemelli, MD, Chiara Elena, MD, Margherita Maffioli, MD, Cristina Bucelli, MD, Marianna Rossi, MD, Mattia Bacciocchi, Elena Maria Elli, MD, Maria Grazia Valsecchi, PhD, Laura Antolini, PhD, Carlo Gambacorti-Passerini, MD

Blood (2018) 132 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2018-99-115208

Published: 2018

Journal Articles

Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients

Blood (2018) 132 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2018-99-115318

Published: 2018

Journal Articles

The role of JAK2 inhibitors in MPNs 7 years after approval

Francesco Passamonti, Margherita Maffioli

Blood (2018) 131 (22): 2426–2435.

https://doi.org/10.1182/blood-2018-01-791491

Published: 2018

Journal Articles

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Blood (2017) 129 (24): 3227–3236.

https://doi.org/10.1182/blood-2017-01-761999

Published: 2017

Includes: Supplemental data

Journal Articles

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Paola Guglielmelli, PhDMD, Giada Rotunno, MSc, PhD, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Daniela Pietra, PhD, Silvia Salmoiraghi, BSc, Carmela Mannarelli, MSc, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 943.

https://doi.org/10.1182/blood.V128.22.943.943

Published: 2016

Journal Articles

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Paola Guglielmelli, MD PhD, Giada Rotunno, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Daniela Pietra, PhD, Daniela Cilloni, MD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 351.

https://doi.org/10.1182/blood.V126.23.351.351

Published: 2015

Journal Articles

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Nicolaus Kröger, Toni Giorgino, Bart L. Scott, Markus Ditschkowski, Haefaa Alchalby, Francisco Cervantes, Alessandro Vannucchi, Mario Cazzola, Enrica Morra, Tatjana Zabelina, Margherita Maffioli, Arturo Pereira, Dietrich Beelen, H. Joachim Deeg, Francesco Passamonti

Blood (2015) 125 (21): 3347–3350.

https://doi.org/10.1182/blood-2014-10-608315

Published: 2015

Journal Articles

Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression

Margherita Maffioli, MD, Francisco Cervantes, MD PhD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD, Enrica Morra, Domenica Caramazza, MD PhD, Barbara Mora, MD, Toni Giorgino, PhD, Francesco Passamonti, MD

Blood (2014) 124 (21): 3187.

https://doi.org/10.1182/blood.V124.21.3187.3187

Published: 2014

Journal Articles

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

Blood (2014) 124 (21): 3179.

https://doi.org/10.1182/blood.V124.21.3179.3179

Published: 2014

Journal Articles

Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients

Nicolaus Kröger, MD, Toni Giorgino, PhD, Bart L Scott, MD, Marcus Ditschkowski, MD, Haefaa Alchalby, MD, Francisco Cervantes, MD PhD, Alessandro M. Vannucchi, MD, Mario Cazzola, MD, Enrica Morra, Tatjana Zabelina, MD, Margherita Maffioli, MD, Arturo Pereira, MD PhD, Dietrich Beelen, MD, H. Joachim Deeg, MD, Francesco Passamonti, MD

Blood (2014) 124 (21): 633.

https://doi.org/10.1182/blood.V124.21.633.633

Published: 2014

Journal Articles

Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients

Blood (2014) 124 (21): 1824.

https://doi.org/10.1182/blood.V124.21.1824.1824

Published: 2014

Journal Articles

A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM)

Blood (2014) 124 (21): 1826.

https://doi.org/10.1182/blood.V124.21.1826.1826

Published: 2014

NARROW

A Population-Based Study on Survival of 652 Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in Italy

Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera

A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study

Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients

The role of JAK2 inhibitors in MPNs 7 years after approval

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients

Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients

A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only